UC Berkeley's DNA-editing technology spinout has raised $10m from RA Capital in addition to the $65m it pocketed in November.

Metagenomi, a US-based gene editing technology spinout of University of California, Berkeley, received $10m in additional series A financing from RA Capital Management to bring the round to $75m. RA Capital is co-leading the round with chemical and pharmaceutical producer Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund. The first tranche in…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.